


## Transdermal Peptide Disulfide TFA

<b>Cat. No.:</b>	HY-P1565A
<b>Molecular Formula:</b>	C <sub>42</sub> H <sub>65</sub> F <sub>3</sub> N <sub>14</sub> O <sub>18</sub> S <sub>2</sub>
<b>Molecular Weight:</b>	1175.17
<b>Sequence Shortening:</b>	ACSSSPSKHCG (Disulfide bridge: Cys2-Cys10)
<b>Target:</b>	Na <sup>+</sup> /K <sup>+</sup> ATPase
<b>Pathway:</b>	Membrane Transporter/Ion Channel
<b>Storage:</b>	Sealed storage, away from moisture
	Powder    -80°C    2 years
	-20°C    1 year
	* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)



### SOLVENT & SOLUBILITY

<b>In Vitro</b>	H <sub>2</sub> O : 100 mg/mL (85.09 mM; Need ultrasonic)					
		Solvent Concentration	Mass	1 mg	5 mg	10 mg
	<b>Preparing Stock Solutions</b>	1 mM	0.8509 mL	4.2547 mL	8.5094 mL	
		5 mM	0.1702 mL	0.8509 mL	1.7019 mL	
10 mM		0.0851 mL	0.4255 mL	0.8509 mL		
Please refer to the solubility information to select the appropriate solvent.						
<b>In Vivo</b>	1. Add each solvent one by one: PBS Solubility: 100 mg/mL (85.09 mM); Clear solution; Need ultrasonic					

### BIOLOGICAL ACTIVITY

<b>Description</b>	Transdermal Peptide Disulfide TFA (TD 1 Disulfide(peptide) TFA) is a 11-amino acid peptide, binds to Na <sup>+</sup> /K <sup>+</sup> -ATPase beta-subunit (ATP1B1), and mainly interacts with the C-terminus of ATP1B1. Transdermal Peptide Disulfide TFA can enhance the transdermal delivery of many macromolecules <sup>[1]</sup> .
<b>In Vitro</b>	In the presence of Transdermal Peptide Disulfide, because of the specific binding of Transdermal Peptide Disulfide to ATP1B1, cells will upregulate the level of ATP1B1 to maintain function and structure; as a result, the expression of ATP1B1 increases. However, as time goes on, some Transdermal Peptide Disulfide molecules may be transported into cells by endocytosis; consequently, the expression of ATP1B1 then decreases. The interaction between Transdermal Peptide Disulfide and ATP1B1 changes not only the expression of ATP1B1, but also the localization of ATP1B1 and then the structure of the epidermal layer. This interaction can be attenuated by inhibitors or competitors, which would result in the reduced delivery of macromolecular drugs across the skin <sup>[1]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

---

## REFERENCES

---

[1]. Wang C, et al. Role of the Na(+)/K(+)-ATPase beta-subunit in peptide-mediated transdermal drug delivery. Mol Pharm. 2015 Apr 6;12(4):1259-67.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA